Retrospective single center observational study of usefulness and safety of golimumab in patients with inflammatory bowel diseases for two years

Retrospective single center observational study of usefulness and safety of golimumab in patients with inflammatory bowel diseases for two years - Retrospective single center observational study of usefulness and safety of golimumab in patients with inflammatory bowel diseases for two years

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056702

Enrollment

130

Registered

2025-03-01

Start date

2025-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients treated with golimumab in our hospital

Exclusion criteria

Exclusion criteria: 1. patients who called us to refuse to join this study 2. patients whose information was not able to extract from their patient's record

Design outcomes

Primary

Measure	Time frame
persistence of golimumab treatment at the induction, one and two year	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp0492283564

Outcome results